Bill Gerhart

Bill Gerhart is an accomplished executive with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as a Board Member at Pulmovant and the Chief Executive Officer of Kinevant Sciences, Bill is focused on developing new therapeutics for rare inflammatory and autoimmune diseases, particularly a monoclonal antibody for pulmonary sarcoidosis. Bill has held significant roles at Roivant Sciences as an Entrepreneur In Residence and has been a Trustee of Sanford Burnham Prebys, where leadership as Chair of the Board began in 2022. Prior leadership positions include CEO roles at Respivant Sciences, Patara Pharma, Elevation Pharmaceuticals, and Mpex Pharmaceuticals, with notable successes such as the acquisition of companies and raising substantial funding for innovative therapies. Bill holds an MBA from Harvard Business School and a BBA from Baylor University.